Tocilizumab

(Actemra®)

Tocilizumab

Drug updated on 11/16/2023

Dosage FormInjection (intravenous; 80 mg/4 mL (20 mg/mL), 200 mg/10 mL (20 mg/mL), 400 mg/20 mL (20 mg/mL)) Injection (subcutaneous; 162 mg/0.9 mL)
Drug ClassInterleukin-6 (IL-6) receptor antagonist
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For treatment of rheumatoid arthritis (RA): adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs).
  • For treatment of giant cell arteritis (GCA): adult patients with giant cell arteritis.
  • For treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD): Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
  • For treatment of polyarticular juvenile idiopathic arthritis (PJIA): patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis.
  • For treatment of systemic juvenile idiopathic arthritis (SJIA): patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
  • For treatment of cytokine release syndrome (CRS): adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome.
  • For treatment of coronavirus disease 2019 (COVID-19): hospitalized adult patients with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Product Monograph / Prescribing Information

Document TitleYearSource
Actemra (tocilizumab) Prescribing Information.2022Genentech, Inc. South San Francisco, CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Genetic biomarkers as predictors of response to tocilizumab in rheumatoid arthritis: a systematic review and meta-analysis.2022Genes
Effectiveness of tocilizumab in the treatment of hospitalized adults COVID-19: a systematic review and meta-analysis.2022Medicine
Efficacy and harms of tocilizumab for the treatment of COVID-19 patients: a systematic review and meta-analysis.2022PLOS ONE
Australian public assessment report for tocilizumab (rch).2022Australian Government Department of Health
The use of tocilizumab in patients with COVID-19: a systematic review, meta-analysis and trial sequential analysis of randomized controlled studies.2021Journal of Clinical Medicine
Tocilizumab and systemic corticosteroids in the management of patients with COVID-19: a systematic review and meta-analysis.2021International Journal of Infectious Diseases
Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: a systematic review and meta-analysis.2021Reviews in Medical Virology
Tocilizumab administration for the treatment of hospitalized patients with COVID-19: a systematic review and meta-analysis.2021Respirology
Safety and efficacy of tocilizumab for rheumatoid arthritis: a systematic review and meta-analysis of clinical trial studies.2021Reumatologia
Tocilizumab in the treatment of COVID-19—a meta-analysis.2021QJM; an International Journal of Medicine
Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review.2021Pulmonology
Assessment report: RoActemra.2021EMA
Effectiveness of tocilizumab in Behcet's disease: a systematic literature review.2020Seminars in Arthritis and Rheumatism
Tocilizumab for the treatment of TAFRO syndrome: a systematic literature review.2020Annals of Hematology
Tocilizumab for severe COVID-19: a systematic review and meta-analysis.2020International Journal of Antimicrobial Agents
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis.2020Clinical Microbiology and Infection
Efficacy of tocilizumab in COVID-19: a systematic review and meta-analysis.2020Journal of Medical Virology
Assessment report: RoActemra.2018EMA
Clinical review report; tocilizumab (Actemra).2018CADTH

Clinical Practice Guidelines